GATC Health Corp Expands Commercial Advisory Board with the Addition of Darius Naigamwalla

GATC Health, a technology company using advanced multiomic analysis and disruptive artificial intelligence to revolutionize disease detection and drug development, today announced that Darius Naigamwalla has joined the company’s Commercial Advisory Board. With executive management experience in biopharma, healthcare technology and medical devices, Mr. Naigamwalla will help GATC Health create and execute its corporate strategy, cementing its position as a leader in assisting biopharma organizations optimize their discovery and development efforts.

Mr. Naigamwalla brings over 20 years’ experience in biopharma services with Campbell Alliance, inVentiv Health (now Syneos), CEEK Enterprises, Two Labs and Envision Pharma Services. He has a broad range of therapeutic area experience covering oncology, immunology, cardiology, endocrinology, anti-infectives, dermatology, neurology and gastroenterology. During his career as a management consultant, Mr. Naigamwalla developed and led corporate strategy and implementation engagements for dozens of different biopharma companies resulting in substantial value creation

“Darius’s biopharma experience and his track record in advising companies in creating value comes at a critical time for our company and our platform,” noted Jeff Moses, President of GATC Health. “He will be instrumental in both optimizing our business strategy and helping us build connections across the industry that will help maximize the potential of our platform and help realize the vision that GATC was built on: using advanced AI to detect diseases earlier and discover better drugs faster.”

Mr. Naigamwalla is currently an Executive Vice President at Two Labs Pharma Services, a leading pharmaceutical consulting company that provides corporate strategy, brand management, product launch, market access and market intelligence services, to manufacturers during the pre-launch period through to loss of exclusivity. Prior to being acquired by Two Labs, Mr. Naigamwalla was the President of CEEK Enterprises, a specialized management consultancy focused on biopharma and healthcare that he founded. He was previously a board member of Beacon Discovery, a world leader in GPCR-focused drug discovery and helped facilitate the sale of that business to Eurofins.

“I'm excited to have the opportunity to collaborate with GATC,” said Mr. Naigamwalla. “The platform technology is one of the best kept secrets in the industry with the potential to completely revolutionize drug discovery and development paradigms. It's time for this technology to shine.”About GATC HealthGATC Health Corp is a pioneering technology company using whole genome analysis and disruptive multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. GATC’s patented technologies deliver enormous benefits for its partners and customers by reducing risk, time and costs. GATC Health’s innovations accelerate healthcare’s transition to individualized medicine.DisclaimerThe information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.